News
VYGR
7.57
-1.05%
-0.08
Weekly Report: what happened at VYGR last week (0415-0419)?
Weekly Report · 3d ago
Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Voyager Therapeutics (NASDAQ:VYGR) has a return on equity of 56% . The ROE is a measure of how much profit a company can generate from its earnings. The company earned 56% in the last year. This is a high rate of return, even compared to the industry average of 16%. Voyager Therapeutic has a good ROE, but its share price is down 14%. The company has an impressive earnings growth rate of 44% over the last five years. Check out the booming earnings growth of VoyagerTherapeutics       
Simply Wall St · 04/17 11:30
Optimistic Buy Rating for Voyager Therapeutics Amid Strong Pipeline and Strategic Partnerships
TipRanks · 04/17 09:07
VOYAGER THERAPEUTICS INC: EXPECT TO FILE AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION WITH FDA FOR PROGRAM IN 2025
Reuters · 04/16 11:00
VOYAGER THERAPEUTICS ANNOUNCES SELECTION OF DEVELOPMENT CANDIDATE FOR GBA1 PROGRAM IN COLLABORATION WITH NEUROCRINE BIOSCIENCES, TRIGGERING MILESTONE PAYMENT
Reuters · 04/16 11:00
VOYAGER THERAPEUTICS:ELIGIBLE TO RECEIVE ADDITIONAL FUTURE DEVELOPMENT & COMMERCIALIZATION MILESTONE PAYMENTS BASED ON FURTHER ADVANCEMENT OF PROGRAM
Reuters · 04/16 11:00
Weekly Report: what happened at VYGR last week (0408-0412)?
Weekly Report · 04/15 09:18
Weekly Report: what happened at VYGR last week (0401-0405)?
Weekly Report · 04/08 09:19
Voyager Therapeutics Said Co And CFO Peter P. Pfreundschuh Entered Into A Transition, Separation And Release Of Claims Agreement; Pfreundschuh Resigned From His Position AsCFO Effective On April 12, 2024
Benzinga · 04/02 20:36
VOYAGER THERAPEUTICS INC- PURSUANT TO AGREEMENT PFREUNDSCHUH RESIGNED FROM HIS POSITION OF CHIEF FINANCIAL OFFICER EFFECTIVE ON APRIL 12, 2024
Reuters · 04/02 20:34
Voyager Therapeutics Announces CFO Transition Plan and Appointment
TipRanks · 04/02 20:24
Weekly Report: what happened at VYGR last week (0325-0329)?
Weekly Report · 04/01 09:18
Buy Voyager Stock, Analyst Says. The Little Biotech Could Have Big Breakthroughs.
Analysts say Voyager Therapeutics stock could more than double if its novel approaches for attacking Alzheimer's disease prove out. The biotech firm's stock has fallen as low as $2.50 from a peak of $30 eight years ago. The company's most advanced program is an antibody that targets the tangled filaments in Alzheimer's.
Barron‘s · 03/30 07:00
Voyager Therapeutics Price Target Announced at $22.00/Share by Guggenheim
Dow Jones · 03/26 10:49
Voyager Therapeutics Initiated at Buy by Guggenheim
Dow Jones · 03/26 10:49
Guggenheim Initiates Coverage On Voyager Therapeutics with Buy Rating, Announces Price Target of $22
Benzinga · 03/26 10:39
Weekly Report: what happened at VYGR last week (0318-0322)?
Weekly Report · 03/25 09:19
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
H.C. Wainwright initiated coverage on Voyager Therapeutics Inc (NASDAQ:VYGR) with a Buy rating and a price target of $30. The analyst says Voyager’s TRACER capsid discovery platform has best-in-class potential for developing CNS-targeted in vivo gene therapies. The company is developing novel capsids to overcome limitations of central nervous system delivery.
Benzinga · 03/19 18:16
Voyager Therapeutics Initiated at Buy by HC Wainwright & Co.
Dow Jones · 03/19 11:01
Voyager Therapeutics Price Target Announced at $30.00/Share by HC Wainwright & Co.
Dow Jones · 03/19 11:01
More
Webull provides a variety of real-time VYGR stock news. You can receive the latest news about Voyager Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VYGR
Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimer’s disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.